Dr. O'Shaughnessy on the Future of TNBC Treatment

Joyce A. OShaughnessy, MD
Published: Thursday, Sep 15, 2011

Joyce A. O'Shaughnessy, MD, Breast Cancer Research, Baylor Sammons Cancer Center in Dallas, TX, discusses the future of triple-negative breast cancer (TNBC) treatments.

O'Shaughnessy believes that TNBC is the biggest challenge currently facing breast cancer treatment. There is currently a large amount of testable hypotheses that may result in a major break-through. These hypotheses will further be strengthened by the results of the The Cancer Genome Atlas (TCGA) project for breast cancer.

The TCGA results should be submitted by the end of this year. A full sequence analysis of breast cancer will not only illuminate TNBC but also will shed light on potential subtypes of TNBC.

Joyce A. O'Shaughnessy, MD, Breast Cancer Research, Baylor Sammons Cancer Center in Dallas, TX, discusses the future of triple-negative breast cancer (TNBC) treatments.

O'Shaughnessy believes that TNBC is the biggest challenge currently facing breast cancer treatment. There is currently a large amount of testable hypotheses that may result in a major break-through. These hypotheses will further be strengthened by the results of the The Cancer Genome Atlas (TCGA) project for breast cancer.

The TCGA results should be submitted by the end of this year. A full sequence analysis of breast cancer will not only illuminate TNBC but also will shed light on potential subtypes of TNBC.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x